RLMD dropped its Q1 results on May 12 and filed a mixed-shelf offering the same evening — two developments that together define the stock's near-term tension: a credible clinical story advancing toward a mid-2026 Phase 3 start, and a capital structure that is clearly not closed.
The earnings print was a marginal miss. Q1 net loss of $0.22 per share came in a penny wide of consensus, against $0.58 a year ago as the company burns through its war chest to fund the NDV-01 bladder cancer program. CEO Sergio Traversa pointed to $234 million in cash — secured via a $160 million private placement completed in March — as sufficient runway through 2029. The shelf filing that hit the SEC the same evening tells a slightly more cautious story: management has kept the capital-raising machinery on standby, size undisclosed. The May 27 analyst day is the next scheduled event.
The short positioning heading into this week was in active retreat — and the borrow market confirms the bears are losing conviction. Short interest as a percentage of the free float fell from around 6.4% at the start of the week to roughly 5.9% by May 12, the lowest reading since early April's sharp jump from 4.1% to above 6.5%. That April step-change, which nearly doubled the short base in the space of a week, was likely tied to the Phase 2 data release and the equity offering. Since that peak near 7.3% in mid-April, shorts have trimmed steadily. Borrow availability is extremely loose — utilisation has dropped to just 0.4% of the pool, compared to a 52-week high of 65% — meaning there is no squeeze pressure of any kind in the lending market. Cost to borrow has been choppy, spiking briefly to 2.5% on May 8 before retreating to 0.8%, and remains well within the range of the past six months.
Options positioning is firmly bullish. The put/call ratio is running at just 0.03, a fraction of its 20-day average of 0.06 and far below the 52-week high of 0.52. Call volume has been dominant for several consecutive weeks, with the ratio collapsing from around 0.19 in early April to current levels. That shift coincided almost exactly with the short interest jump — the two markets were telling opposite stories through April. Now they are aligned: options traders are leaning bullish and short sellers are covering.
Analyst coverage picked up sharply in March and remains constructive, though the most recent formal actions are now approaching two months old. Mizuho maintained its Outperform rating and raised its target from $10 to $19 on March 20. Piper Sandler initiated with Overweight and a $12 target on March 24. Lucid Capital Markets started coverage at Buy with a $14 target in early March. Consensus across the coverage universe sits at a mean target around $13 against a current price of $7.45, implying material upside in the eyes of the Street — though RLMD is pre-revenue and all coverage is recent enough to predate the Q1 print. Valuation multiples are broadly uninformative for a clinical-stage company, with the EV/EBITDA deeply negative and the price-to-book near 6x.
The institutional picture that emerged from end-2025 13F filings shows significant fresh buying. Adage Capital, Spruce Street, Marshall Wace, OrbiMed, Columbia, Millennium, and Braidwell all appeared as new holders in December 2025 filings — a broad sweep of sophisticated healthcare investors taking positions around the same time the private placement was being assembled. Janus Henderson, already the largest institutional holder at 7.1% of shares, added modestly. Commodore Capital filed a fresh 13G on April 27, disclosing a 1.3 million share position. That filing coincided with the week shorts began to cover, worth noting as a directional signal of professional positioning.
On the clinical side, the Q1 call centred almost entirely on NDV-01 in non-muscle invasive bladder cancer. Twelve-month Phase 2 data showed a 76% complete response rate in the overall high-risk population and 80% in the BCG-unresponsive subgroup — numbers management called best-in-class. No patient progressed to muscle-invasive disease. The RESCUE Phase 3 program targets mid-2026 initiation with FDA alignment confirmed. A provisional patent application filed in April could extend commercial exclusivity to 2047 if granted. The sepranolone program in Prader-Willi syndrome is also targeting a proof-of-concept study start in mid-2026. The shelf filing filed on the evening of May 13 keeps all financing options open as the company moves from Phase 2 to two simultaneous Phase 3-level programs — the next major binary for the stock is whether RESCUE enrolment begins on schedule.
See the live data behind this article on ORTEX.
Open RLMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
